Opinion|Videos|March 14, 2025
Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment
Panelists discuss how health care institutions have established structured care pathways for nonspecialist providers to evaluate mild cognitive impairment and mild dementia, incorporating validated questionnaires, standardized screening protocols, and clear referral guidelines to ensure consistent assessment across diverse clinical settings.
Advertisement
Video content above is prompted by the following:
- Have you created a care pathway for nonspecialist providers to use when evaluating patients for mild cognitive impairment or mild dementia?
- If so, can you describe the pathway? For example, do you use validated questionnaires or standardized screening protocols?
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
3
Oral Iberdomide May Widen Myeloma Access: Mateo Mejia Saldarriaga, MD
4
Data Show Upadacitinib Repigments Skin in Nonsegmental Vitiligo
5